SCHEMBL26293249

SCHEMBL26293249

C[C@H](CC(=O)NC(c1ccccc1)(c1ccccc1)c1ccccc1)C(=O)CCl

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.38
LMNA P02545 4/20 0.38
MAPT P10636 2/20 0.38
KIF11 P52732 1/20 0.37
SMN1; SMN2 Q16637 3/20 0.36
HTT P42858 2/20 0.36
KMT2A Q03164 2/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
TP53 P04637 1/20 0.36
KCNN4 O15554 2/20 0.35
CYP1A2 P05177 2/20 0.35
CYP2D6 P10635 1/20 0.35
CNR1 P21554 2/20 0.35
CNR2 P34972 2/20 0.35
GRIN2D O15399 2/20 0.35
GRIN1 Q05586 2/20 0.35
GRIN2A Q12879 2/20 0.35
GRIN2B Q13224 2/20 0.35
GRIN2C Q14957 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12038615 0.84 APAF1 (0.42) ALDH1A1LMNAMAPTKIF11RAB9A
SCHEMBL26292979 0.84 APAF1 (0.42) ALDH1A1LMNAMAPTKIF11RAB9A
SCHEMBL16743931 0.83 MAPT (0.41) ALDH1A1LMNAMAPTKIF11KMT2A
SCHEMBL26294391 0.82 MAPT (0.40) LMNAMAPTKIF11KMT2AKCNN4
SCHEMBL19871023 0.82 MAPT (0.40) LMNAMAPTKIF11KMT2AKCNN4
SCHEMBL26293248 0.81 ALPL (0.45) LMNAMAPTSMN1; SMN2HTTKMT2A
SCHEMBL15249334 0.81 ESRRB (0.47) ALDH1A1MAPTKIF11KMT2AKCNN4
SCHEMBL26293258 0.81 PGR (0.41) ALDH1A1LMNAMAPTSMN1; SMN2KMT2A
SCHEMBL26293357 0.81 ESRRB (0.47) ALDH1A1MAPTKIF11KMT2AKCNN4
SCHEMBL26293222 0.80 HPGD (0.49) ALDH1A1LMNASMN1; SMN2KMT2ACYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230234917-A1 ASPARAGINE DERIVATIVES AND METHODS OF USING SAME SENDA BIOSCIENCES INC (US) 2023-07-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230234917-A1 ASPARAGINE DERIVATIVES AND METHODS OF USING SAME ASNS, SI, NARS1 ALDH1A1 1286/4885LMNA 2652/4885MAPT 3616/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.